The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
H Akamatsu, K Ninomiya, H Kenmotsu… - International journal of …, 2019 - Springer
According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Incidence and risk of xerosis with targeted anticancer therapies
J Valentine, VR Belum, J Duran, K Ciccolini… - Journal of the American …, 2015 - Elsevier
Background Many targeted therapies used in the treatment of cancer can lead to the
development of xerosis, but the incidence and relative risk of xerosis have not been …
development of xerosis, but the incidence and relative risk of xerosis have not been …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in …
Y Liu, Z Ren, J Wang, S Zhang - Thoracic Cancer, 2016 - Wiley Online Library
Background The correlation between epidermal growth factor receptor‐tyrosine kinase
inhibitors (EGFR‐TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic …
inhibitors (EGFR‐TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic …
[HTML][HTML] Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and …
Y Liu, Y Zhang, L Zhang, B Liu, Y Wang, X Zhou, Y Li… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinoma
(ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase …
(ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - journals.plos.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
MS Kamika Reynolds PhD, N Rodriguez-Ormaza… - Clinical Lung Cancer, 2024 - Elsevier
A systematic literature review was conducted to determine the incidence and mortality of QT
interval prolongation (QTp), torsades de pointes (TdP), and heart failure (HF) in patients with …
interval prolongation (QTp), torsades de pointes (TdP), and heart failure (HF) in patients with …
[HTML][HTML] A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy …
K Yamada, H Aono, Y Hosomi, H Okamoto… - European Journal of …, 2015 - Elsevier
Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer …
A Miyanaga, H Asahina, S Watanabe, T Shukuya… - Clinical Lung Cancer, 2023 - Elsevier
Background Platinum-based combination therapy plus a programmed cell death
1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor is a standard treatment for patients …
1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor is a standard treatment for patients …